全球细胞和基因治疗市场：按治疗类型、载体、生产方法、最终用户和地区划分－市场规模、产业动态、机会分析和预测（2025-2035 年）

细胞和基因疗法市场正呈现强劲且加速成长的态势，预计到 2024 年将达到约 365 亿美元。如此可观的市场规模反映了先进疗法在各个疾病领域的快速普及和应用范围的不断扩大。展望未来，预计到 2035 年，该市场将快速成长至约 1,831 亿美元，2026 年至 2035 年的复合年增长率 (CAGR) 为 17.5%。

推动这一成长趋势的关键因素有很多。技术创新是其中最重要的因素，基因编辑、载体开发和生产流程的不断进步使得更有效、更安全、更易于规模化的疗法成为可能。这些突破性进展正在扩大可治疗疾病的范围，改善临床疗效，从而增加患者的治疗机会并提升市场潜力。 此外，慢性病和罕见疾病领域持续存在的未满足医疗需求，也持续推动对新型治疗方案的需求。

市场趋势

细胞和基因治疗市场由诺华、吉利德（透过其子公司Kite）、辉瑞、bluebird bio和安进等大型公司主导。儘管市场集中度较高，但竞争仍然激烈，各公司积极寻求策略联盟，并探索创新的融资模式，以应对先进疗法的高成本。一个显着的例子是按疗效付费协议（OBA）的使用，该协议将支付与CAR-T疗法等疗法的实际临床疗效挂钩，其中包括Yescarta和Zolgensma等知名产品。

2025年12月，产业合作取得了重大进展，SCTbio和Fortrea宣布建立策略联盟，以加速细胞和基因疗法的开发和交付。 此次合作凸显了旨在汇集专业知识、扩大生产能力并简化从研究到患者使用的流程的合作趋势日益增长。

同时，全球科学创新领导者赛默飞世尔科技（Thermo Fisher Scientific）于2025年11月迎来了一个重要的里程碑，其位于费城的东海岸旗舰先进治疗协作中心（ATxCC）正式启用。该中心将是该公司在美国的第二个ATxCC，与位于加州卡尔斯巴德的现有中心形成互补。

2025年10月，龙沙（Lonza）推出新的TheraPEAK®产品－AmpliCell®细胞激素和TheraPEAK® 293-GT®培养基，进一步巩固了其市场地位。这些符合GMP标准的工具旨在提高从研究到生产的整个流程的一致性和生物学相关性。

核心驱动因素

细胞和基因治疗市场的快速显着增长正在推动生产能力的显着扩张，并促进了强大的合约开发和生产组织 (CDMO) 生态系统的发展。随着越来越多的疗法进入临床试验阶段并接近商业化，对符合良好生产规范 (GMP) 的专业生产设施的需求至关重要。确保生产流程符合严格的品质和安全标准，对于确保这些复杂的疗法能够惠及患者至关重要。

新兴机会

在基因医学领域，体内基因编辑正成为一种革命性的趋势，从根本上改变了治疗介入的实施方式。传统方法需要从患者体内提取细胞，在体外进行修饰，然后再重新输注，而体内基因编辑可以直接在患者体内进行 DNA 修饰。这种方法简化了治疗流程，无需复杂的细胞提取和回输程序，使治疗更容易实施，也更容易获得。体内基因编辑的营运优势显着。 更有效率的治疗方案可减少治疗准备和实施所需的时间和资源。

优化障碍

全球私人资金对细胞和基因疗法的投入减少，对市场成长构成重大挑战。私人投资在推动该领域的创新和进步方面发挥着至关重要的作用，尤其是在许多进展高度依赖早期研发的情况下。由于来自创投、私募股权公司和其他私人管道的资金流入减少，企业在获得资助研发管线、进行临床试验以及将新疗法推向市场所需的资源方面面临着重大障碍。资金的减少可能会减缓科学发现的步伐，并延缓有前景的疗法从实验室走向商业化的进程。

目录

第一章：摘要整理：全球细胞与基因治疗市场

第二章：报告概述

• 研究框架
  • 研究目标
  • 市场定义
  • 市场区隔
• 研究方法
  • 市场规模估算
  • 质性研究
  • 量化研究
  • 按地区划分的原始调查受访者细分
  • 资料三角验证
  • 研究假设

第三章：全球细胞与基因治疗市场概述

• 产业价值链分析
  • 材料供应商
  • 製造商
  • 经销商
  • 终端用户
• 行业展望
  • 2020-2035年全球细胞与基因治疗市场
  • 细胞和基因治疗概述：市场趋势和区域趋势
• PESTLE分析
• 波特五力分析
  • 供应商议价能力
  • 买方议价能力
  • 替代品威胁
  • 新进入者威胁
  • 竞争强度
• 市场成长与展望
  • 市场收入估算与预测（2020-2035年）
  • 依疗法划分的价格趋势分析
• 市场吸引力分析
  • 依疗法划分
  • 按地区划分
  • 可操作的洞见（分析师建议）

第四章：竞争格局概览

• 市场集中度
• 公司市占率分析（价值，2025 年）
• 竞争格局分析与基准分析
  • 主要公司（按地区划分）

第五章：全球细胞与基因治疗市场分析

• 市场动态与趋势
  • 成长驱动因素
  • 限制因素
  • 机遇
  • 主要趋势
• 市场机会概述
• 依疗法类型划分
  • 主要发现
  • 市场规模与预测（2020-2035）
  • 细胞疗法
  • 基因疗法
• 依适应症/治疗领域划分
  • 主要发现
  • 市场规模及预测，2020-2035
  • 肿瘤学
  • 实体瘤
  • 遗传性疾病
  • 神经系统疾病
  • 心血管疾病
  • 眼科
  • 肌肉骨骼/骨科疾病
  • 传染病
  • 代谢性疾病
  • 其他
• 依载体型别（基因递送法）划分
  • 主要发现
  • 市场规模及预测，2020-2035
  • 病毒载体
  • 非病毒载体
• 依生产方式划分类型
  • 主要发现
  • 市场规模及预测（2020-2035 年）
  • 内部研发
  • 合约研发生产机构 (CDMO)
  • 混合模式
  • 其他
• 依最终用户划分
  • 关键洞察
  • 市场规模及预测（2020-2035 年）
  • 医院和专科诊所
  • 学术和研究机构
  • 製药和生技公司
  • 政府/公共卫生机构
  • 其他
• 按地区划分
  • 关键洞察
  • 市场规模及预测（2020-2035 年）

第六章 北美细胞与基因治疗市场分析

第七章：欧洲细胞与基因治疗市场分析

第八章：亚太地区细胞与基因治疗市场分析

第九章：中东和非洲细胞和基因治疗市场分析

第十章：南美洲细胞与基因治疗市场分析

第十一章：公司简介

• ALLOGENE THERAPEUTICS
• 安进公司 (Amgen Inc.)
• 安斯泰来药厂 (Astellas Pharma Inc.)
• Atara Biotherapeutics, Inc.
• 拜耳公司 (Bayer AG)
• BioMarin
• Bluebird Bio, Inc.
• 百时美施贵宝公司 (Bristol-Myers Squibb Company)
• 新基公司 (Celgene Corporation)
• Cellectis
• 吉利德科学公司 (Gilead Sciences, Inc.)
• 罗氏公司 (Hoffmann-La Roche)有限公司
• ImmunoACT
• 强生公司
• Krystal Biotech, Inc.
• 诺华公司
• Orchard Therapeutics plc
• Sana Biotechnology
• uniQure NV.
• Vericel Corporation
• 其他

第十二章附录

The cell and gene therapy market is demonstrating a robust and accelerating growth trajectory, with its value reaching an estimated US$ 36.5 billion in 2024. This impressive market size reflects the rapid adoption and expanding applications of these advanced therapies across a range of medical conditions. Looking ahead, projections indicate that the market will soar to an estimated valuation of US$ 183.1 billion by 2035, representing a compound annual growth rate (CAGR) of 17.5% during the forecast period from 2026 to 2035.

Several key factors are driving this upward curve. Technological innovation remains at the forefront, with ongoing advances in gene editing, vector development, and manufacturing processes enabling more effective, safer, and scalable therapies. These breakthroughs are expanding the range of treatable diseases and improving clinical outcomes, thereby enhancing both patient access and market potential. Additionally, the persistent unmet medical needs in chronic and rare diseases continue to fuel demand for novel treatment options.

Noteworthy Market Developments

The cell and gene therapy market is led by major players such as Novartis, Gilead (through its Kite subsidiary), Pfizer, Bluebird Bio, and Amgen. Although the market is semi-consolidated, it remains highly competitive, with companies actively engaging in strategic partnerships and exploring innovative financing models to manage the high costs associated with advanced therapies. One notable example is the use of outcomes-based agreements (OBAs), which link payment to the real-world performance of therapies like CAR-T treatments, including well-known products such as Yescarta and Zolgensma.

In December 2025, the industry witnessed a significant collaboration as SCTbio and Fortrea announced a strategic partnership aimed at accelerating the development and delivery of cell and gene therapies. This collaboration highlights the growing trend of alliances designed to combine expertise, expand manufacturing capabilities, and streamline the path from research to patient access.

Meanwhile, Thermo Fisher Scientific Inc., a global leader in scientific innovation, marked a major milestone in November 2025 by officially opening its East Coast flagship Advanced Therapies Collaboration Center (ATxCC) in Philadelphia. This facility represents the company's second ATxCC in the United States, complementing its existing center in Carlsbad, California.

In October 2025, Lonza further strengthened its position in the market by launching two new TheraPEAK(R) products: AmpliCell(R) Cytokines and TheraPEAK(R) 293-GT(R) Medium. These GMP-compliant tools are designed to enhance consistency and biological relevance across the entire research and manufacturing continuum.

Core Growth Drivers

The rapid and tremendous growth of the cell and gene therapy market is fueling a substantial expansion in manufacturing capabilities, alongside the development of a robust Contract Development and Manufacturing Organization (CDMO) ecosystem. As an increasing number of therapies advance through clinical trials and move closer to commercialization, the demand for specialized production facilities that comply with Good Manufacturing Practices (GMP) has become critically important. Ensuring that manufacturing processes meet stringent quality and safety standards is essential for the successful delivery of these complex therapies to patients.

Emerging Opportunity Trends

In vivo gene editing has emerged as a transformative trend in the field of genetic medicine, fundamentally changing how therapeutic interventions are delivered. Unlike traditional approaches that involve removing cells from a patient's body, modifying them externally, and then reintroducing them, in vivo gene editing allows for direct alterations to a patient's DNA within their body. This method simplifies the treatment process by eliminating the need for complex cell extraction and reinfusion procedures, thereby making therapy administration more straightforward and accessible. The logistical advantages of in vivo gene editing are significant. Treatments can be delivered more efficiently, reducing the time and resources required to prepare and administer therapy.

Barriers to Optimization

A decline in global private funding for cell and gene therapy presents a significant challenge to the market's growth trajectory. Private investment plays a critical role in driving innovation and progression within this sector, particularly because many advancements rely heavily on early-stage research and development. When capital inflows from venture capitalists, private equity firms, and other private sources diminish, companies face substantial obstacles in securing the necessary resources to fund their research pipelines, conduct clinical trials, and bring new therapies to market. This reduction in funding can slow down the pace of scientific discovery and delay the transition of promising therapies from the laboratory to commercial availability.

Detailed Market Segmentation

By Therapy Type, the cell therapy segment captured a significant portion of the revenue share in the cell and gene therapy market in 2024, solidifying its leadership position within the industry. This dominance is largely attributable to a surge of regulatory approvals and increased investment fueling the rapid development and commercialization of cell-based treatments. The approval of new therapies by regulatory agencies not only validates the safety and efficacy of these innovative products but also encourages further research and confidence among investors, healthcare providers, and patients.

By Indication / Therapeutic Area, the infectious disease segment is projected to command the largest market share within the cell and gene therapy industry, reflecting the expanding application of these advanced therapeutic approaches in combating a wide array of infectious conditions. The increasing burden of infectious diseases worldwide, including viral, bacterial, and parasitic infections, has driven a surge in demand for innovative treatments that can effectively target pathogens and enhance immune responses. Cell and gene therapies offer promising solutions by enabling precise interventions at the molecular and cellular levels, which traditional treatments often cannot achieve.

By Vector Type (Gene Delivery Method), the in vivo delivery method dominated in 2024 by capturing the largest revenue share. This prominence is primarily attributed to its high efficiency and versatility, which make it suitable for a broad range of therapeutic applications. Unlike ex vivo methods, where cells are modified outside the body and then reintroduced, in vivo delivery involves directly administering genetic material into the patient's body. This approach simplifies the treatment process, reduces logistical challenges, and holds promise for treating a wider variety of diseases, including those affecting tissues and organs that are difficult to access externally.

By end-users, the cancer care centers hold the lion's share of the cell and gene therapy market, reflecting the high concentration of cancer treatments within this specialized healthcare segment. These centers are at the forefront of adopting advanced therapies as oncologists increasingly integrate cell and gene therapies into their treatment protocols. The growing prevalence of cancer worldwide, coupled with advancements in personalized medicine, has made these therapies a cornerstone for addressing complex and aggressive malignancies that were previously difficult to treat effectively.

Segment Breakdown

By Therapy Type

• Cell Therapy
• Stem Cell Therapy
• T-Cells
• Dendritic Cells
• NK Cells
• Gene Therapy
• In-vivGene Therapy
• Ex-vivGene Therapy
• Gene Editing Therapies
• RNA-Based Therapies
• Others

By Indication / Therapeutic Area

• Oncology
• Solid Tumors
• Genetic Disorders
• Neurological Disorders
• Cardiovascular Diseases
• Ophthalmology
• Musculoskeletal / Orthopedic Disorders
• Infectious Diseases
• Metabolic Disorders
• Others

By Vector Type (Gene Delivery Method)

• Viral Vectors
• Adeno-Associated Virus (AAV)
• Lentivirus
• Retrovirus
• Herpes Simplex Virus (HSV)
• Adenovirus
• Others
• Non-Viral Vectors
• Lipid Nanoparticles (LNPs)
• Naked DNA/RNA Plasmids
• Electroporation
• Gene gun/microinjection
• CRISPR-Cas Delivery Systems (non-viral)
• Others

By Manufacturing Type

• In-house
• Contract Development & Manufacturing Organizations (CDMOs)
• Hybrid Models (e.g., early stage in-house, scale-up outsourced)
• Others

By End User

• Hospitals and Specialty Clinics
• Academic and Research Institutes
• Biopharma and Biotech Companies
• CDMOs and CROS
• Government/Public Health Bodies
• Others

By Region

• North America
• The US
• Canada
• Mexico
• Europe
• Western Europe
• The UK
• Germany
• France
• Italy
• Spain
• Rest of Western Europe
• Eastern Europe
• Poland
• Russia
• Rest of Eastern Europe
• Asia Pacific
• China
• India
• Japan
• Australia and New Zealand
• South Korea
• ASEAN
• Rest of Asia Pacific
• Middle East and Africa
• Saudi Arabia
• South Africa
• UAE
• Rest of MEA
• South America
• Argentina
• Brazil
• Rest of South America

Geography Breakdown

• North America commands a dominant position in the global market, holding over 39.50% of the total share. This leadership is largely driven by the region's strong and unparalleled innovation ecosystem, which fosters cutting-edge research and rapid development across various advanced fields. The region's regulatory environment, particularly in the United States, plays a crucial role in sustaining this momentum. In 2024, the U.S. Food and Drug Administration (FDA) approved nine new cell and gene therapy products, demonstrating a forward-looking and supportive stance toward emerging biotechnologies.
• This positive regulatory climate has spurred an expansive research pipeline, with more than 2,500 active Investigational New Drug (IND) applications for cell and gene therapies currently filed with the FDA. Such a high volume of ongoing research initiatives reflects both the scientific community's enthusiasm and the regulatory agency's willingness to facilitate innovation. The robust pipeline not only signals future market growth but also attracts significant investment and talent to the region.

Leading Market Participants

• ALLOGENE THERAPEUTICS
• Amgen Inc.
• Astellas Pharma Inc.
• Atara Biotherapeutics, Inc.
• Bayer AG
• Biomarin
• Bluebird Bio, Inc.
• Bristol-Myers Squibb Company
• Celgene Corporation
• Cellectis
• Gilead Sciences, Inc.
• Hoffmann-La Roche Ltd
• ImmunoACT
• Johnson & Johnson
• Krystal Biotech, Inc
• Novartis AG
• Orchard Therapeutics plc
• Sana Biotechnology
• uniQure NV.
• Vericel Corporation
• Other Prominent Players

Table of Content

Chapter 1. Executive Summary: Global Cell And Gene Therapy Market

Chapter 2. Report Description

• 2.1. Research Framework
  • 2.1.1. Research Objective
  • 2.1.2. Market Definitions
  • 2.1.3. Market Segmentation
• 2.2. Research Methodology
  • 2.2.1. Market Size Estimation
  • 2.2.2. Qualitative Research
    • 2.2.2.1. Primary & Secondary Sources
  • 2.2.3. Quantitative Research
    • 2.2.3.1. Primary & Secondary Sources
  • 2.2.4. Breakdown of Primary Research Respondents, By Region
  • 2.2.5. Data Triangulation
  • 2.2.6. Assumption for Study

Chapter 3. Global Cell And Gene Therapy Market Overview

• 3.1. Industry Value Chain Analysis
  • 3.1.1. Material Provider
  • 3.1.2. Manufacturer
  • 3.1.3. Distributor
  • 3.1.4. End User
• 3.2. Industry Outlook
  • 3.2.1. Global Cell And Gene Therapy Market, 2020-2035 (in US$ Mn)
  • 3.2.2. Overview of Cell and Gene Therapy: Market and Regional Developments
• 3.3. PESTLE Analysis
• 3.4. Porter's Five Forces Analysis
  • 3.4.1. Bargaining Power of Suppliers
  • 3.4.2. Bargaining Power of Buyers
  • 3.4.3. Threat of Substitutes
  • 3.4.4. Threat of New Entrants
  • 3.4.5. Degree of Competition
• 3.5. Market Growth and Outlook
  • 3.5.1. Market Revenue Estimates and Forecast (US$ Mn), 2020-2035
  • 3.5.2. Price Trend Analysis, By Therapy Type
• 3.6. Market Attractiveness Analysis
  • 3.6.1. By Therapy Type
  • 3.6.2. By Region
  • 3.6.3. Actionable Insights (Analyst's Recommendations)

Chapter 4. Competition Dashboard

• 4.1. Market Concentration Rate
• 4.2. Company Market Share Analysis (Value %), 2025
• 4.3. Competitor Mapping & Benchmarking
  • 4.3.1. Key players - By Region

Chapter 5. Global Cell And Gene Therapy Market Analysis

• 5.1. Market Dynamics and Trends
  • 5.1.1. Growth Drivers
  • 5.1.2. Restraints
  • 5.1.3. Opportunity
  • 5.1.4. Key Trends
• 5.2. Market Opportunity Snapshot
• 5.3. By Therapy Type
  • 5.3.1. Key Insights
  • 5.3.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 5.3.2.1. Cell Therapy
      • 5.3.2.1.1. Stem Cell Therapy
      • 5.3.2.1.2. T-Cells
      • 5.3.2.1.3. Dendritic Cells
      • 5.3.2.1.4. NK Cells
    • 5.3.2.2. Gene Therapy
      • 5.3.2.2.1. In-vivGene Therapy
      • 5.3.2.2.2. Ex-vivGene Therapy
      • 5.3.2.2.3. Gene Editing Therapies
      • 5.3.2.2.4. RNA-Based Therapies
      • 5.3.2.2.5. Others
• 5.4. By Indication / Therapeutic Area
  • 5.4.1. Key Insights
  • 5.4.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 5.4.2.1. Oncology
    • 5.4.2.2. Solid Tumors
    • 5.4.2.3. Genetic Disorders
    • 5.4.2.4. Neurological Disorders
    • 5.4.2.5. Cardiovascular Diseases
    • 5.4.2.6. Ophthalmology
    • 5.4.2.7. Musculoskeletal / Orthopedic Disorders
    • 5.4.2.8. Infectious Diseases
    • 5.4.2.9. Metabolic Disorders
    • 5.4.2.10. Others
• 5.5. By Vector Type (Gene Delivery Method)
  • 5.5.1. Key Insights
  • 5.5.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 5.5.2.1. Viral Vectors
      • 5.5.2.1.1. Adeno-Associated Virus (AAV)
      • 5.5.2.1.2. Lentivirus
      • 5.5.2.1.3. Retrovirus
      • 5.5.2.1.4. Herpes Simplex Virus (HSV)
      • 5.5.2.1.5. Adenovirus
      • 5.5.2.1.6. Others
    • 5.5.2.2. Non-Viral Vectors
      • 5.5.2.2.1. Lipid Nanoparticles (LNPs)
      • 5.5.2.2.2. Naked DNA/RNA Plasmids
      • 5.5.2.2.3. Electroporation
      • 5.5.2.2.4. Gene gun / microinjection
      • 5.5.2.2.5. CRISPR-Cas Delivery Systems (non-viral)
      • 5.5.2.2.6. Others
• 5.6. By Manufacturing Type
  • 5.6.1. Key Insights
  • 5.6.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 5.6.2.1. In-house
    • 5.6.2.2. Contract Development & Manufacturing Organizations (CDMOs)
    • 5.6.2.3. Hybrid Models (e.g., early stage in-house, scale-up outsourced)
    • 5.6.2.4. Others
• 5.7. By End User
  • 5.7.1. Key Insights
  • 5.7.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 5.7.2.1. Hospitals and Specialty Clinics
    • 5.7.2.2. Academic and Research Institutes
    • 5.7.2.3. Biopharma and Biotech Companies
    • 5.7.2.4. CDMOs and CROS
    • 5.7.2.5. Government/Public Health Bodies
    • 5.7.2.6. Others
• 5.8. By Region
  • 5.8.1. Key Insights
  • 5.8.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 5.8.2.1. North America
      • 5.8.2.1.1. The U.S.
      • 5.8.2.1.2. Canada
      • 5.8.2.1.3. Mexico
    • 5.8.2.2. Europe
      • 5.8.2.2.1. Western Europe
        • 5.8.2.2.1.1. The UK
        • 5.8.2.2.1.2. Germany
        • 5.8.2.2.1.3. France
        • 5.8.2.2.1.4. Italy
        • 5.8.2.2.1.5. Spain
        • 5.8.2.2.1.6. Rest of Western Europe
      • 5.8.2.2.2. Eastern Europe
        • 5.8.2.2.2.1. Poland
        • 5.8.2.2.2.2. Russia
        • 5.8.2.2.2.3. Rest of Eastern Europe
    • 5.8.2.3. Asia Pacific
      • 5.8.2.3.1. China
      • 5.8.2.3.2. India
      • 5.8.2.3.3. Japan
      • 5.8.2.3.4. South Korea
      • 5.8.2.3.5. Australia & New Zealand
      • 5.8.2.3.6. ASEAN
        • 5.8.2.3.6.1.1. Indonesia
        • 5.8.2.3.6.1.2. Malaysia
        • 5.8.2.3.6.1.3. Thailand
        • 5.8.2.3.6.1.4. Singapore
        • 5.8.2.3.6.1.5. Rest of ASEAN
      • 5.8.2.3.7. Rest of Asia Pacific
    • 5.8.2.4. Middle East & Africa
      • 5.8.2.4.1. UAE
      • 5.8.2.4.2. Saudi Arabia
      • 5.8.2.4.3. South Africa
      • 5.8.2.4.4. Rest of MEA
    • 5.8.2.5. South America
      • 5.8.2.5.1. Argentina
      • 5.8.2.5.2. Brazil
      • 5.8.2.5.3. Rest of South America

Chapter 6. North America Cell And Gene Therapy Market Analysis

• 6.1. Market Dynamics and Trends
  • 6.1.1. Growth Drivers
  • 6.1.2. Restraints
  • 6.1.3. Opportunity
  • 6.1.4. Key Trends
• 6.2. Market Size and Forecast, 2020-2035 (US$ Mn)
  • 6.2.1. By Therapy Type
  • 6.2.2. By Indication / Therapeutic Area
  • 6.2.3. By Vector Type (Gene Delivery Method)
  • 6.2.4. By Manufacturing Type
  • 6.2.5. By End User
  • 6.2.6. By Region

Chapter 7. Europe Cell And Gene Therapy Market Analysis

• 7.1. Market Dynamics and Trends
  • 7.1.1. Growth Drivers
  • 7.1.2. Restraints
  • 7.1.3. Opportunity
  • 7.1.4. Key Trends
• 7.2. Market Size and Forecast, 2020-2035 (US$ Mn)
  • 7.2.1. By Therapy Type
  • 7.2.2. By Indication / Therapeutic Area
  • 7.2.3. By Vector Type (Gene Delivery Method)
  • 7.2.4. By Manufacturing Type
  • 7.2.5. By End User
  • 7.2.6. By Region

Chapter 8. Asia Pacific Cell And Gene Therapy Market Analysis

• 8.1. Market Dynamics and Trends
  • 8.1.1. Growth Drivers
  • 8.1.2. Restraints
  • 8.1.3. Opportunity
  • 8.1.4. Key Trends
• 8.2. Market Size and Forecast, 2020-2035 (US$ Mn)
  • 8.2.1. By Therapy Type
  • 8.2.2. By Indication / Therapeutic Area
  • 8.2.3. By Vector Type (Gene Delivery Method)
  • 8.2.4. By Manufacturing Type
  • 8.2.5. By End User
  • 8.2.6. By Region

Chapter 9. Middle East & Africa Cell And Gene Therapy Market Analysis

• 9.1. Market Dynamics and Trends
  • 9.1.1. Growth Drivers
  • 9.1.2. Restraints
  • 9.1.3. Opportunity
  • 9.1.4. Key Trends
• 9.2. Market Size and Forecast, 2020-2035 (US$ Mn)
  • 9.2.1. By Therapy Type
  • 9.2.2. By Indication / Therapeutic Area
  • 9.2.3. By Vector Type (Gene Delivery Method)
  • 9.2.4. By Manufacturing Type
  • 9.2.5. By End User
  • 9.2.6. By Region

Chapter 10. South America Cell And Gene Therapy Market Analysis

• 10.1. Market Dynamics and Trends
  • 10.1.1. Growth Drivers
  • 10.1.2. Restraints
  • 10.1.3. Opportunity
  • 10.1.4. Key Trends
• 10.2. Market Size and Forecast, 2020-2035 (US$ Mn)
  • 10.2.1. By Therapy Type
  • 10.2.2. By Indication / Therapeutic Area
  • 10.2.3. By Vector Type (Gene Delivery Method)
  • 10.2.4. By Manufacturing Type
  • 10.2.5. By End User
  • 10.2.6. By Region

Chapter 11. Company Profile (Company Overview, Financial Matrix, Key Product landscape, Key Personnel, Key Competitors, Contact Address, and Business Strategy Outlook)

• 11.1. ALLOGENE THERAPEUTICS
• 11.2. Amgen Inc.
• 11.3. Astellas Pharma Inc.
• 11.4. Atara Biotherapeutics, Inc.
• 11.5. Bayer AG
• 11.6. Biomarin
• 11.7. Bluebird Bio, Inc.
• 11.8. Bristol-Myers Squibb Company
• 11.9. Celgene Corporation
• 11.10. Cellectis
• 11.11. Gilead Sciences, Inc.
• 11.12. Hoffmann-La Roche Ltd
• 11.13. ImmunoACT
• 11.14. Johnson & Johnson
• 11.15. Krystal Biotech, Inc
• 11.16. Novartis AG
• 11.17. Orchard Therapeutics plc
• 11.18. Sana Biotechnology
• 11.19. uniQure NV.
• 11.20. Vericel Corporation
• 11.21. Other Prominent Players

Chapter 12. Annexure

• 12.1. List of Secondary Sources
• 12.2. Key Country Markets- Macro Economic Outlook/Indicators